Here are 1-3 brief analogies for Syndax Pharmaceuticals:

• An early-stage Genentech (part of Roche) for highly targeted cancer and immune-related therapies.
• Like a developing Vertex Pharmaceuticals (VRTX) specializing in precision medicines for specific, difficult-to-treat diseases.

• SNDX-5613: A drug candidate in clinical trials for the treatment of MLL-rearranged and nucleophosmin 1 mutant acute myeloid leukemia.
• SNDX-6352 (axatilimab): A monoclonal antibody designed to treat patients with chronic graft versus host disease.
• Entinostat: A drug candidate also under development by the company.

Syndax Pharmaceuticals (SNDX) is a clinical-stage biopharmaceutical company focused on the development of therapies for the treatment of cancer. Its lead product candidates, SNDX-5613 and SNDX-6352 (axatilimab), are currently in Phase 1/2 clinical trials and are not yet approved for commercial sale.

Therefore, Syndax Pharmaceuticals does not currently have major customers from the sale of marketed pharmaceutical products. As a clinical-stage company, its primary activities are research and development, rather than commercial sales to other companies or individuals.

Michael A. Metzger, Chief Executive Officer and Director

Mr. Metzger has served as Chief Executive Officer of Syndax Pharmaceuticals since February 2022, and previously as President and Chief Operating Officer from May 2015. He also joined the company's board of directors in July 2019. Prior to Syndax, he was President, Chief Executive Officer, and a Director of Regado Biosciences, Inc., where he oversaw the company's merger with Tobira Therapeutics, Inc. in 2015. Tobira Therapeutics was later acquired by Allergan. His career also includes executive leadership roles at Mersana Therapeutics, Forest Laboratories (acquired by Allergan), and Onconova Therapeutics. He was also a Managing Director at MESA Partners, Inc., a venture capital firm. Mr. Metzger has served on the board of CTI Biopharma Corp., which was acquired by SOBI AB in 2023.

Keith A. Goldan, Chief Financial Officer, Treasurer and Chief Accounting Officer

Mr. Goldan joined Syndax Pharmaceuticals as Chief Financial Officer in June 2022. He brings nearly 30 years of experience in finance and operations across pharmaceutical, biotechnology, and medical technology companies. Prior to Syndax, he was the Chief Financial Officer of Optinose, a publicly traded specialty pharmaceutical company, where he helped build infrastructure for product launch. He also held CFO roles at Fibrocell, NuPathe (a privately held specialty pharmaceutical company that raised venture financing), PuriCore plc, and Biosyn. Mr. Goldan has successfully led multiple initial public offerings, capital markets transactions, and merger and acquisition transactions throughout his career.

Briggs W. Morrison, M.D., President, Head of Research & Development

Dr. Morrison transitioned to President, Head of Research & Development in February 2022, after serving as Chief Executive Officer of Syndax Pharmaceuticals from 2015. He has held significant leadership positions in major pharmaceutical companies, including Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, Head, Medical Affairs, Safety and Regulatory Affairs at Pfizer, and Vice President, Clinical Sciences, Oncology, at Merck & Co. Dr. Morrison is also an Entrepreneur Partner at MPM BioImpact (formerly MPM Capital), a venture capital firm, and serves on the boards of several public and private biotechnology companies.

Peter Ordentlich, Ph.D., Co-Founder and Chief Scientific Officer

Dr. Ordentlich co-founded Syndax Pharmaceuticals in October 2005. He previously served as Chief Technology Officer, Vice President, Translational Medicine, and Executive Director, Translational Science at Syndax. Before founding Syndax, Dr. Ordentlich was a research scientist at X-Ceptor Therapeutics, Inc., a drug discovery company that was acquired by Exelixis, Inc.

Steven Closter, Chief Commercial Officer

Mr. Closter serves as the Chief Commercial Officer at Syndax Pharmaceuticals. He is involved in the company's commercial strategy and the launch of its approved medicines, Revuforj and Niktimvo.

• Clinical Trial and Regulatory Approval Risk: As a clinical-stage biopharmaceutical company, Syndax Pharmaceuticals' success is heavily dependent on the successful outcome of its ongoing and future clinical trials for lead product candidates like SNDX-5613, SNDX-6352 (axatilimab), and Entinostat. The failure of any of these candidates in clinical trials or an inability to obtain necessary regulatory approvals would significantly and adversely impact the company's business, financial condition, and prospects.
• Dependence on Limited Product Pipeline: Syndax Pharmaceuticals' value is largely tied to the development and commercialization success of a small number of product candidates. The company's future revenue and growth are highly reliant on the successful progression and ultimate approval of SNDX-5613, axatilimab, and Entinostat. Any setback, delay, or failure in the development or commercialization of these specific candidates would have a material adverse effect on the company.

Syndax Pharmaceuticals' main products target significant addressable markets in oncology and immunology.

SNDX-5613 (Revumenib) for MLL-rearranged (MLLr) and NPM1 mutant (NPM1m) Acute Myeloid Leukemia (AML)

• The overall global acute myeloid leukemia (AML) treatment market was valued at approximately USD 3.47 billion in 2024 and is projected to reach USD 6.29 billion by 2030, with a Compound Annual Growth Rate (CAGR) of 10.6% from 2025 to 2030. North America is the largest market, accounting for a 37.6% share in 2024, with the U.S. market contributing 90.9% of North America's share.
• For relapsed/refractory (R/R) acute myeloid leukemia with susceptible nucleophosmin 1 (NPM1m) and KMT2A-rearranged (KMT2Ar) mutations, the U.S. addressable market opportunity is estimated to be approximately USD 2 billion.
• NPM1-mutant AML accounts for approximately 30% of new AML cases annually. MLL rearrangements are found in up to 10% of all acute leukemias.
• In the frontline setting, the market opportunity for revumenib is projected to exceed USD 5 billion.
• Globally, Revumenib's revenue is forecast to reach an annual total of USD 707 million by 2033.

SNDX-6352 (Axatilimab) for Chronic Graft versus Host Disease (cGVHD)

• The global graft versus host disease (GvHD) treatment market size was valued at USD 3.08 billion in 2025 and is projected to grow to USD 6.34 billion by 2034, at a CAGR of 8.35%.
• The U.S. GvHD market was valued at approximately USD 965 million in 2024.
• Chronic GvHD (cGVHD) constitutes nearly 42% of the total GvHD treatment market.
• A study indicated that 42% of U.S. patients developed cGVHD within three years post-allogeneic hematopoietic stem cell transplantation (HSCT). About 50% of patients with cGVHD require three or more lines of therapy, and axatilimab is approved for chronic GvHD after failure of at least two prior lines of systemic therapy.

Expected Drivers of Future Revenue Growth for Syndax Pharmaceuticals (SNDX)

Syndax Pharmaceuticals (SNDX) is anticipated to drive future revenue growth over the next 2-3 years through several key avenues, primarily centered on the expanding commercialization of its two lead product candidates, Revuforj (SNDX-5613) and Niktimvo (SNDX-6352 or axatilimab), as well as pipeline advancements.

1. Continued Commercial Uptake and Market Penetration of Revuforj: Revuforj (revumenib) demonstrated strong early commercial success, generating $125 million in net revenue in its first full year of sales in 2025, with a notable 38% increase in net revenue and 35% growth in prescriptions quarter-over-quarter in Q4 2025. The approval in NPM1-mutated Acute Myeloid Leukemia (AML) in Q4 2025 is expected to sustain this growth, alongside an increasing average duration of therapy in KMT2A patients. Syndax plans for additional label expansions and increased physician engagement to further drive demand.
2. Expanding Commercial Success and Profitability of Niktimvo: Niktimvo (axatilimab) has also shown significant commercial traction since its launch, contributing $42.4 million in collaboration revenue to Syndax in 2025 from $151.6 million in net revenue reported by its partner. The treatment has demonstrated high persistency in a chronic setting, with 60-70% of patients remaining on therapy at month ten, and has been prescribed by 90% of U.S. bone marrow transplant centers, capturing approximately 20% of the third-line-plus chronic Graft Versus Host Disease (cGVHD) market within eleven months of launch. Syndax anticipates increasing profitability margins from Niktimvo as its revenues continue to grow.
3. Potential Label Expansion of Revuforj into Frontline AML: A significant growth driver is the ongoing pivotal global enrollment of Revuforj in newly diagnosed NPM1 and KMT2A AML. The company initiated a pivotal frontline trial of revumenib plus venetoclax and azacitidine in mNPM1 and KMT2Ar AML in Q1 2025, which represents a substantial expansion into a broader patient population with high unmet medical needs.
4. Pipeline Expansion of Axatilimab into Idiopathic Pulmonary Fibrosis (IPF): Syndax has completed enrollment of the Phase 2 MAXPIRe trial for axatilimab in idiopathic pulmonary fibrosis (IPF), with top-line data expected in Q4 2026. A successful outcome from this trial, potentially followed by an additional Phase 3 trial, could lead to FDA approval and open up a significant new market opportunity for axatilimab beyond cGVHD.

Share Issuance

• Syndax Pharmaceuticals completed an underwritten public offering on December 14, 2022, issuing 7,840,909 shares of common stock at a price of $22.00 per share, which included the full exercise of the underwriters' option to purchase additional shares.
• This offering resulted in approximately $172.5 million in gross proceeds for the company.
• In late February 2026, Syndax Pharmaceuticals filed a shelf registration for US$77.73 million, representing 3,746,239 common shares, for an ESOP-related offering.

Inbound Investments

• Syndax secured a $350 million royalty funding agreement with Royalty Pharma, tied to Niktimvo's U.S. net sales, which is anticipated to help fund the company's operations through to profitability.
• Morgan Stanley significantly increased its investment in Syndax Pharmaceuticals, adding 4,475,024 shares to its portfolio at $13.22 per share on December 31, 2024.
• Sphera Funds Management Ltd. made an estimated $6.54 million investment in Syndax Pharmaceuticals, purchasing 374,847 shares in the fourth quarter of 2025.

Capital Expenditures

• For the third quarter of 2025, Syndax Pharmaceuticals reported capital expenditures of $187,000.
• The company's management stated in June 2024 that existing cash, cash equivalents, and short-term investments as of June 30, 2022, were expected to fund projected operating expenses and capital expenditure requirements for at least the subsequent 12 months.